{
    "Allocation": "Randomized",
    "CompleteTime": 6,
    "DesignModel": "Crossover Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "brv vs lev in randomized double blinded, crossover fashion: 100 mg approximately 2 weeks later , ",
                "ArmGroupLabel": "Part 1",
                "ArmGroupType": "Active Comparator",
                "InterventionDescription": [
                    {
                        "Dosage": "100 mg",
                        "DrugName": "brv vs lev in randomized double blinded, crossover fashion",
                        "Duration": "approximately 2 weeks later",
                        "HowToTake": ""
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "Drug: BRV vs LEV in randomized double blinded, crossover fashion"
                    ]
                }
            },
            {
                "ArmGroupDescription": "brv vs lev in randomized double blinded, crossover fashion: 100 mg approximately 2 weeks later , ",
                "ArmGroupLabel": "Part 2",
                "ArmGroupType": "Active Comparator",
                "InterventionDescription": [
                    {
                        "Dosage": "100 mg",
                        "DrugName": "brv vs lev in randomized double blinded, crossover fashion",
                        "Duration": "approximately 2 weeks later",
                        "HowToTake": ""
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "Drug: BRV vs LEV in randomized double blinded, crossover fashion"
                    ]
                }
            }
        ]
    },
    "Enrollment": "16",
    "InterventionName": "",
    "Masking": "Triple",
    "NCTID": "NCT03580707",
    "Objective": "Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint",
    "OfficialTitle": "Does BRV Have a Faster Onset Time and Greater Effect Than LEV in Epilepsy Patients?: A Prospective, Randomized, Crossover, Double-blind, Controlled Intravenous Study Using the PPR as a Pharmacodynamic Efficacy Endpoint",
    "PopulationBox": {
        "Condition": "Photosensitive Epilepsy",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "65 Years",
        "MinAge": "18 Years",
        "Participant": "16"
    },
    "PopulationRatio": "",
    "Title": "Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint",
    "WashoutPeriod": ""
}